Starling Oncology, Inc. (STLNW) Stock buybacks 2021–2024
Starling Oncology, Inc. (STLNW) annual stock buyback history — cash paid to repurchase common stock, per SEC filings.
$0FY2024 · since FY2021: $0 → $0
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $0 | -100.0% |
| FY2023 | $1.0M | -88.7% |
| FY2022 | $9.0M | — |
| FY2021 | $0 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Operating cash flowSTLNW Free cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →